AXONE-Acute II: Acute Assessment of a Micro Multipolar Lead for Enhanced Cardiac Resynchronisation Therapy (AXONE-Acute-2)

June 26, 2020 updated by: University Hospital, Rouen
Pilot study to evaluate the performance of a lead below 2 French with specific distal shape to deliver efficient LV pacing

Study Overview

Status

Unknown

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Bordeaux, France
        • Recruiting
        • Bordeaux University Hospital
        • Contact:
          • Philippe RITTER, Pr
      • Clermont-Ferrand, France
        • Recruiting
        • Clermont-Ferrand University Hospital
        • Contact:
          • Frédéric Jean, MD
      • Lille, France
        • Recruiting
        • Lille University Hospital
        • Contact:
          • Didier KLUG, Pr
      • Rennes, France
        • Recruiting
        • Rennes University Hospital
        • Contact:
          • Christophe LECLERCQ, Pr
      • Rouen, France
        • Recruiting
        • Rouen University Hospital
      • Badalona, Spain
        • Recruiting
        • Hospital Universitari Germans Trias i Pujol
        • Contact:
          • Roger VILLUENDAS, MD
      • Valencia, Spain
        • Recruiting
        • Hospital Universitario y Politécnico La Fe
        • Contact:
          • Joaquín OSCA, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female patient aged ≥18 years old.
  • Patient presenting a CRT-P or CRT-D indication according to the latest ESC guidelines1.
  • Primary implant of a CRT device (including upgrade from a single or dual-chamber pacemaker or ICD).
  • Signed and dated informed consent.

Exclusion Criteria:

  • Class IV of NYHA (ambulatory or not).
  • Allergy to contrast media used for imaging during cardiac catheterization.
  • Severe Renal Failure (clearance of creatinine according to Modification of diet in renal disease formula (MDRD) < 30ml/mn/m²).
  • Previous failure of catheterization of the coronary sinus, or previous failure of left ventricular lead implantation.
  • Already included in another clinical study involving intra-cardiac active implantable device, or participation to any other clinical trial in the last 2 weeks.
  • Vulnerable patient such as person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision).
  • Known pregnancy, breastfeeding or women in childbearing age without an adequate contraceptive method with a known failure rate < 1%.-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Implant test procedure
Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
LV Bi-zone pacing success rate
Time Frame: 30 min
Percent of patients where the placement of the AXONE lead provides two distant LV pacing vectors matching: Pacing Threshold ≤ 3.5V/0.5ms.
30 min
LV pacing success rate
Time Frame: 30 min
Percent of patients where the placement of the AXONE lead allows at least one LV pacing vectors matching: Pacing Threshold ≤ 3.5V/0.5ms.
30 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Device or Implant testing procedure-related Adverse Events
Time Frame: 1 month post intervention
1 month post intervention
Electrical performance (1)
Time Frame: 30 min
LV pacing threshold (Volt)
30 min
Electrical performance (2)
Time Frame: 30 min
LV pacing impedance (Ohm)
30 min
AXONE Implant Efficiency (1)
Time Frame: 30 min
procedure time for successful placement
30 min
AXONE Implant Efficiency (2)
Time Frame: 30 min
fluoroscopic time
30 min
AXONE Implant Efficiency (3)
Time Frame: 30 min
radiation dose
30 min
AXONE Implant Efficiency (4)
Time Frame: 30 min
handling assessment.
30 min
LV multipoint pacing success
Time Frame: 30 min
the placement of the AXONE provides two pacing vectors matching
30 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 2, 2020

Primary Completion (ANTICIPATED)

October 1, 2020

Study Completion (ANTICIPATED)

October 1, 2020

Study Registration Dates

First Submitted

November 5, 2019

First Submitted That Met QC Criteria

November 6, 2019

First Posted (ACTUAL)

November 7, 2019

Study Record Updates

Last Update Posted (ACTUAL)

June 29, 2020

Last Update Submitted That Met QC Criteria

June 26, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 2019/127/HP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Resynchronisation Therapy

Clinical Trials on Implant test procedure

3
Subscribe